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Abstract
Introduction: American women of African ancestry (AA) are more likely than European Americans (EA) to have
estrogen receptor (ER)-negative breast cancer. 25-hydroxyvitamin D (25OHD) is low in AAs, and was associated
with ER-negative tumors in EAs. We hypothesized that racial differences in 25OHD levels, as well as in inherited
genetic variations, may contribute, in part, to the differences in tumor characteristics.
Methods: In a case (n = 928)-control (n = 843) study of breast cancer in AA and EA women, we measured serum
25OHD levels in controls and tested associations between risk and tag single nucleotide polymorphisms (SNPs) in
VDR, CYP24A1 and CYP27B1, particularly by ER status.
Results: More AAs had severe vitamin D deficiency (< 10 ng/ml) than EAs (34.3% vs 5.9%), with lowest levels among
those with the highest African ancestry. Associations for SNPs differed by race. Among AAs, VDR SNP rs2239186,
associated with higher serum levels of 25OHD, decreased risk after correction for multiple testing (OR = 0.53, 95% CI =
0.31-0.79, p by permutation = 0.03), but had no effect in EAs. The majority of associations were for ER-negative breast
cancer, with seven differential associations between AA and EA women for CYP24A1 (p for interaction < 0.10). SNP
rs27622941 was associated with a > twofold increased risk of ER-negative breast cancer among AAs (OR = 2.62, 95% CI
= 1.38-4.98), but had no effect in EAs. rs2209314 decreased risk among EAs (OR = 0.38, 95% CI = 0.20-0.73), with no
associations in AAs. The increased risk of ER-negative breast cancer in AAs compared to EAs was reduced and became
non-significant (OR = 1.20, 95% CI = 0.80-1.79) after adjusting for these two CYP24A1 SNPs.
Conclusions: These data suggest that genetic variants in the vitamin D pathway may be related to the higher
prevalence of ER-negative breast cancer in AA women.
Introduction
American women of African ancestry (AA) are more
likely to develop breast cancer at a younger age than
those with European ancestry (EA) and are more likely
to have tumors with aggressive characteristics, including
high histological grade, negative estrogen receptor (ER)
status, and basal-like - ER- and/or progesterone receptor
(PR)-, HER2-, and cytokeratin 5/6+ and/or HER1+ -fea-
tures [1,2]. The reasons for these racial disparities are
unknown.
It is clear that, among geographically diverse popula-
tions, certain genotypic and phenotypic characteristics
may be selected for in response to local environmental
pressures [3]. Skin pigmentation, the primary factor that
provides protection from ultraviolet (UV) radiation, is
correlated with latitude, and dark skin pigmentation is
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likely to be the original ancestral trait in humans. Migra-
tions to Europe and Asia eventually gave rise to
decreased pigmentation and lighter skin [4-6]. As much
as 90% of vitamin D is derived from sun exposure, but
high skin melanin concentration prevents penetration of
UVB light and compromises synthesis efficiency by 10 to
50 times [7]. Although high pigmentation would reduce
absorption of vitamin D, intense sun exposure in sub-
Saharan Africa would compensate. However, in high-lati-
tude areas where UVB intensity is low and where more
time may be spent indoors (particularly in winter), vita-
min D deficiency may result among individuals with
higher skin pigmentation. Indeed, in the US, the preva-
lence of 25-hydroxyvitamin D (25OHD) of less than 15
ng/mL is almost 10 times higher in AA than in EA
women [8], and the prevalence of severe vitamin D defi-
ciency (< 10 ng/mL) among AAs was 29% in 2001 to
2004 [9]. In contrast, in Guinea-Bissau, the average
25OHD levels in healthy Africans were 34 ng/mL, and
the prevalence of severe vitamin D deficiency was as low
as 1% [10].
Endogenous 25OHD may also be affected by variabil-
ity in metabolic pathways, and synthesis and metabolism
catalyzed by two major enzymes, 1a-hydroxylase and
24-hydroxylase, which are encoded by CYP27B1 and
CYP24A1, respectively. Binding of vitamin D to the vita-
min D receptor (VDR) activates or suppresses gene tran-
scription, depending on the type of response elements
[11], and genetic variability in the above genes, known
to differ by ancestry [12], is likely to affect vitamin D
signaling.
Laboratory, preclinical, and clinical findings support the
hypothesis that low levels of vitamin D are related to
breast cancer risk. In the human mammary gland, VDR is
expressed in all cell types [13], and vitamin D treatment
inhibits breast cancer cell proliferation, induces cell apop-
tosis, and prevents carcinogenesis in rodent models
[14,15]. However, epidemiologic evidence for associations
between vitamin D and breast cancer risk is considered
‘limited’ [16], and one randomized trial showed little
impact of vitamin D supplementation on breast cancer
incidence [17]. These inconclusive findings could be due
to tumor heterogeneity, which implies that the effects of
vitamin D may only present in specific breast cancer sub-
types. In fact, Vdr knockout mice were more likely than
their wild-type littermates to develop Er/Pr- tumors [18].
Consistent with results from these preclinical studies,
some epidemiologic studies have also indicated that effects
of vitamin D may be strongest for breast cancers with
poor prognostic characteristics and that lower serum
25OHD levels are found among women with ER- com-
pared with ER+ tumors [19-21]. Recently, we reported
lower levels of serum 25OHD in women with high- versus
low-grade breast tumors and in women with triple-nega-
tive versus luminal A breast tumors [22].
Here, we examined levels of 25OHD in AA and EA
women without breast cancer in relation to self-reported
race as well as ancestry, which was estimated by using
ancestry informative markers (AIMs). 25OHD levels in
women with breast cancer could be a result of disease pro-
cesses, and some samples were obtained after chemother-
apy was initiated; thus, we did not compare serum levels
of 25OHD between cases and controls. Instead, we evalu-
ated variants in vitamin D activity and major metabolism
(VDR, CYP27B1, and CYP24A1) in relation to breast can-
cer risk, particularly in relation to self-reported race and
estrogen receptor status. We also tested whether vitamin
D-related genetic variants could explain, in part, the higher
prevalence of ER- breast cancer among AA women.
Materials and methods
Study population
The Women’s Circle of Health Study (WCHS) is an
ongoing study designed specifically to examine the role
of genetic and non-genetic factors in early/aggressive
breast cancer in AA and EA women. Study design,
enrollment, and collection of data and biospecimens have
been described in detail previously [23]. Briefly, women
with diagnosed incident breast cancer were identified
through both hospital-based case ascertainment in tar-
geted hospitals that had large referral patterns of AAs in
four boroughs of the metropolitan New York City area
and population-based case ascertainment in seven coun-
ties in New Jersey through the New Jersey State Cancer
Registry. The eligibility criteria for cases were the follow-
ing: self-identified AA and EA women, 20 to 75 years of
age at diagnosis, no previous history of cancer other than
non-melanoma skin cancer, recent diagnosis of primary,
histologically confirmed breast cancer, and English-
speaking. EA women with breast cancer, more prevalent
in the catchment area than AA cases, were randomly
selected for recruitment and were matched by age and
county to AA cases. Controls who did not have a history
of diagnosis of any cancer other than non-melanoma
skin cancer and who were living in the same area as cases
were identified through random digit dialing and were
matched to cases by self-reported race and 5-year age
categories. After agreement to participate was obtained,
in-person interviews were conducted to complete
informed consent and to query participants on a number
of potential risk factors, including medical history, family
history of cancer, diet, physical activity, and other lifestyle
factors. Anthropometric measures were taken, and bios-
pecimens were collected. Blood samples were initially
collected, but owing to logistical and cost constraints, we
transitioned to saliva samples after the enrollment of
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approximately 850 participants. Permission to obtain
pathology data, including ER status, and tumor tissue
blocks was included in the informed consent form. The
participation rates were 80.2% and 53.4% for AA cases
and controls, respectively, and 80.0% and 48.9% for EA
cases and controls, respectively. This study was approved
by the institutional review boards of the Roswell Park
Cancer Institute, the Cancer Institute of New Jersey, the
Mount Sinai School of Medicine, and the participating
hospitals in New York City. At the time of the genotyping
(April 2010), DNA and data were available for 553 AA
cases and 466 AA controls and 383 EA cases and 382 EA
controls from the WCHS.
Selection of multi-population tag single-nucleotide
polymorphisms
We used a two-step approach to select a set of multi-
population tag single-nucleotide polymorphisms (SNPs)
that represent common genetic variations - minor allele
frequency of at least 0.05 - in VDR in both AA and EA
populations. First, 122 SNPs in the VDR region plus 15-kb
regions from both 3’ and 5’ ends were selected from Hap-
Map [24] and other resequencing projects by using the
Genome Variation Server at SeattleSNPs [25]. These SNPs
were then genotyped in 60 AA and 60 EA controls. With
the TAGster program [26], 49 multi-population tag SNPs
were subsequently selected for genotyping in the WCHS.
Also among those VDR variants finally selected were com-
monly studied SNPs, including Cdx2 (rs11568820), Fok1
(rs2228570), Bsm1 (rs1544410), Apa1 (rs7975232), and
Taq1 (rs731236). For CYP24A1, 15 multi-population tag
SNPs were selected by using publicly available CEU (Utah
residents with ancestry from Northern and Western Eur-
ope) and YRI (Yoruba in Ibadan) genotype data from Hap-
Map. For CYP27B1, only one SNP had a minor allele
frequency of at least 0.05 in the dbSNP database and was
thus included. To control for potential bias due to popula-
tion admixture and to examine serum 25OHD levels in
relation to ancestry, a panel of 108 AIMs that have been
shown to be effective in correcting for admixture in case-
control studies [27] was chosen.
Genotyping
DNA was extracted from blood samples by using Flexi-
Gene™ DNA kits (Qiagen, Valencia, CA, USA) in accor-
dance with the instructions of the manufacturer and from
saliva collected in Oragene™ kits (DNA Genotek Inc.,
Kanata, ON, Canada). Genomic DNA was evaluated and
quantified by a Nanodrop UV spectrometer (Thermo
Fisher Scientific Inc., Wilmington, DE, USA) and a Pico-
Green-based fluorometric assay (Molecular Probes, now
part of Invitrogen Corporation, Carlsbad, CA, USA) and
stored at -80°C until analysis. Selected tag SNPs and AIMs
were genotyped by an Illumina GoldenGate assay (Illumina
Inc., San Diego, CA, USA) at the Genomics Core Facility at
the Roswell Park Cancer Institute. Five percent duplicates
and two sets of in-house trio samples were included for
quality control purposes. The average successful genotyp-
ing rate for each sample and each SNP was at least 99%,
and no SNPs violated Hardy-Weinberg equilibrium in con-
trols or mendelian inheritance. Clustering plots of SNPs
that were significant in the statistical analysis were manu-
ally re-inspected post hoc to ensure that the calls were
robust.
Measurement of serum levels of 25OHD in WCHS controls
Serum samples were available from 242 AA and 187 EA
women in the control group and were used to measure
levels of 25OHD by immunochemiluminometric assay.
The assay coefficient of variation was 10.3%.
Statistical analysis
Estimation of ancestry and comparison of serum levels of
25OHD
Individual ancestral proportions for EA and AA were esti-
mated with the Bayesian Markov chain Monte Carlo clus-
tering algorithm implemented in STRUCTURE 2.3 [28].
We included publicly available genotypes from the YRI
and CEU ancestral populations, and the program was run
multiple times assuming K = 2 underlying ancestries.
Women with more than 85% of genomic race other than
the self-identified race were excluded from the analysis (n
= 13); therefore, 547 AA cases and 461 AA controls and
381 EA cases and 382 EA controls were included in the
final analyses for SNPs and breast cancer risk. There were
no exclusions due to conflicting self-report and marker
ancestry in the serum analyses performed in controls only.
To compare serum levels of 25OHD between AA and EA
women, least squares means and standard errors were cal-
culated with adjustment for age, body mass index (BMI),
and season of blood collection (four seasons). To test gen-
otype-phenotype correlations between SNPs and 25OHD
levels in controls, the Pearson correlation test was used
and genotypes were coded as 0, 1, and 2 to reflect the
number of copies of the minor allele.
Associations between breast cancer risk and genotypes and
haplotypes
Descriptive variables were analyzed by Student t test or
chi-squared test. All genotype analyses were performed for
AA and EA populations separately. A genotypic (co-domi-
nant) model was assumed for SNP effects. When genotype
frequencies of the rare homozygote were not more than
5% in both populations, categories were collapsed (homo-
zygote rare and heterozygote) for power considerations.
To test whether there was a linear dose effect of the var-
iant alleles (log-additive genetic model for trend test),
SNPs were coded as 0, 1, and 2 as described above. Uni-
variate single SNP analysis was performed, and resulting
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P values were plotted after logarithm transformation with
accompanying linkage disequilibrium (LD) map by using
the snp.plotter R package [29]. Covariates, including age at
diagnosis, BMI, European ancestry, family history of breast
cancer, and education, were then adjusted in multivariate
logistic regression models to derive odds ratios (ORs) and
95% confidence intervals (CIs).
For VDR and CYP24A1, haplotype structure was deter-
mined by using the method of Gabriel and colleagues [30],
and each haplotype was tested in the regression model in
comparison with all other haplotypes. For both single SNP
and haplotype analyses, we controlled the family-wise
error rate by using permutation testing (n = 10,000) as
implemented in PLINK [31].
Potential modification of associations by race, menopausal
status, and estrogen receptor status
To examine whether the associations of SNPs with breast
cancer risk differed between AA and EA women, interac-
tion with race was tested by including a race*SNP term in
the logistic regression model without an estimate of ances-
try. A similar approach was used to test modification
effects by menopausal status.
To test whether selected SNPs contributed to differential
risk of ER- breast cancer between AA and EA women, OR
of ER- breast cancer by race was first estimated from a
base model containing race and other covariates. SNPs
that were differentially associated with ER- breast cancer
risk by race (P for interaction was less than 0.10) were
then entered in the base model and subjected to backward
selection. A substantial reduction of OR (≥ 10%) for AA
versus EA race by adding selected SNPs would indicate
that those SNPs explained, in part, the higher risk of ER-
breast cancer in AA than in EA women.
Results
Descriptive characteristics
Table 1 summarizes the descriptive characteristics of the
study population by self-reported race. The majority of the
women were pre-menopausal at the time of cancer diag-
nosis (62%) or enrollment for controls (57%). Overall, AA
women had higher BMIs than EA women (31.3 versus
27.2 kg/m2) and were less likely to have a college educa-
tion or beyond (57.5% versus 82.0%), to take hormone
replacement therapy after menopause (14.0% versus
24.1%), or to have a family history of breast cancer in first-
degree relatives (13.5% versus 22.4%) (all P < 0.001). There
were no significant case-control differences in AAs or
EAs, except that in EA women, cases were less likely than
controls to have a college education and more likely to
have a positive family history of breast cancer (P ≤ 0.001).
Serum levels of 25OHD
Among controls, serum levels of 25OHD were lower in
AA than EA women (least squares means and standard
errors after age, BMI, and season of blood collection
were controlled for: 14.9 ± 0.5 versus 21.4 ± 0.6 ng/mL;
P < 0.001). As shown in Figure 1a, the rate of vitamin D
severe deficiency (< 10 ng/mL) was almost sixfold higher
in AA than EA women (34.3% versus 5.9%). On the
basis of publicly available gene expression data in cul-
tured lymphoblastoid cell lines (LCLs) from the Hap-
Map CEU and YRI populations [32], estimated average
expression levels of VDR were significantly lower in
LCLs from the African population than in those from
the European population (log2-transformed level mean ±
standard deviation: 6.54 ± 0.47 versus 6.96 ± 0.53; q
value after controlling for multiple comparison: 1.30 ×
10-5) (Figure 1b). We categorized AA women by propor-
tion of African ancestry (< 85%, 85% to 94%, and ≥ 95%)
and found that women with the lowest African ancestry
had the highest serum 25OHD levels (15.5 ng/mL) but
that those with the greatest African ancestry (≥ 95%)
had the lowest levels (13.7 ng/mL) (P = 0.07). When
correlations between SNPs and serum 25OHD levels in
AA and EA women were tested, the minor allele of
VDR SNP rs2239186 was significantly associated with
increased levels of 25OHD in AAs. For the AA, AG,
and GG genotypes, the means and standard deviations
of serum 25OHD were 13.5 ± 6.5, 16.3 ± 8.7, and 21.2
± 12.2 ng/mL, respectively (P = 0.006). However, the
differences were not significant in EA women (21.0,
23.8, and 22.1 ng/mL for the AA, AG, and GG geno-
types, respectively; P = 0.20).
Associations between genetic variants and breast cancer
risk by self-reported race
In addition to circulating 25OHD levels, there were racial
differences in genetic variants. Of the 65 SNPs genotyped,
51 (79%) displayed significantly different allele frequencies
by self-reported race (P < 0.05); 12 of these SNPs were the
rare variant in one group (AA or EA) but the common
allele in the other group (Table S1 of Additional file 1).
LD in VDR and CYP24A1 also displayed different patterns
by race, as shown in Figures 2 and 3. Also shown in the
figures are unadjusted P values for associations between
single SNPs and breast cancer risk (see Table S1 of Addi-
tional file 1 for results of all SNPs). In AA women, four
SNPs in VDR - rs12721364, rs2239186, rs886441, and
rs11568820 (Cdx2) - but none in CYP24A1 were asso-
ciated with breast cancer risk at a nominal significance
level of 0.05 (Figures 2a and 3a). The association of VDR
rs2239186 remained significant after correction for multi-
ple testing (P = 0.03). In EA women, two SNPs in VDR -
rs11608702 and rs7975332 (Apa1) - and three SNPs in
CYP24A1 - rs912505, rs3787555, and rs2244719 - were
associated with breast cancer risk (P < 0.05) (Figures 2b
and 3b) but did not remain significant after multiple com-
parisons were controlled for (data not shown). There were
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no associations between the SNP in CYP27B1 and breast
cancer risk in either EA or AA women.
Table 2 shows ORs and 95% CIs for four SNPs
(rs11608702, rs12721364, rs2239186, and rs11568820) in
VDR and two SNPs (rs912505 and rs3787555) in
CYP24A1 which had differential associations between AA
and EA women (P for interaction by race was not more
than 0.10) after adjustment for age, proportion of Eur-
opean ancestry, BMI, family history of breast cancer, and
education. In AA women, the combined GG and AG gen-
otypes of rs2239186, which remained significant after cor-
rection for multiple testing and were also related to
increased levels of 25OHD, were associated with an almost
50% reduction of risk of breast cancer in comparison with
homozygotes for A alleles (OR = 0.53, 95% CI = 0.35 to
0.79, P trend for the G allele = 0.001). Among AA women,
a reduced risk associated with VDR rs12721364 (OR =
0.53, 95% CI = 0.31 to 0.79, P = 0.01) and a marginally
increased risk with SNP rs11568820 (Cdx2) (OR for AA
genotypes = 1.94, 95% CI = 1.01 to 3.74, P = 0.04) were
observed.
Among EA women, the VDR ’at-risk’ G allele for
rs2239186 was more common in EA women but was not
associated with breast cancer risk (OR = 0.85, 95% CI =
0.62 to 1.17), nor were VDR rs12721364 SNPs. There
were increases in risk by the VDR SNP rs11608702 and
significant decreases in risk by two CYP24A1 variants:
rs912505 and rs3787555; however, these did not remain
significant after correction for multiple testing.
Results from haplotype analysis were consistent with
those from single SNP analysis for VDR rs2239186.
Among AA women, a G-G-G haplotype consisting of this
SNP and two neighboring variants was associated with a
decreased risk of breast cancer after adjustment for multi-
ple testing (OR = 0.55, 95% CI = 0.38 to 0.81, P = 0.04)
(Table S2 of Additional file 1). Among EA women, similar
results were found for haplotypes containing rs11608702
in VDR and haplotypes containing rs3787555 in CYP24A1.
The commonly studied haplotype in the 3’ untranslated
region of VDR consisting of Taq1, Apa1, and Bsm1 was
not associated with breast cancer risk in AA women, but a
modest decreased risk was observed in EA women and
significance was marginal (OR = 0.82, 95% CI = 0.67 to
1.02).
Estrogen receptor-negative breast cancer and CYP24A1
variants
Stratification by ER status revealed associations that
were not observed in the overall analysis, and the major-
ity of findings were observed only for ER- breast cancer
(Tables S3 and S4 of Additional file 1). Although VDR
rs10783218 was marginally associated with a twofold
increased risk of ER+ breast cancer among EA women
and VDR rs3819545 was associated with a decreased
Table 1 Descriptive characteristics of African-American and European-American women by case-control status in the
Women’s Circle of Health Study
African-American European-American
Characteristics Case
(n = 547)
Control
(n = 461)
P value Case
(n = 381)
Control
(n = 382)
P value
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age, years 51.7 (10.0) 49.8 (9.9) 0.003 51.0 (8.4) 50.9 (8.3) 0.82
Body mass index, kg/m2 31.2 (6.7) 31.6 (7.8) 0.48 26.8 (5.8) 27.7 (7.1) 0.06
Percentage with European ancestry 0.09 (0.15) 0.10 (0.16) 0.19 0.98 (0.07) 0.99 (0.03) 0.07
Count (%) Count (%) Count (%) Count (%)
Menopausal status 0.14 0.17
Pre-menopausal 337 (61.6) 263 (57.0) 235 (61.7) 217 (56.8)
Post-menopausal 210 (38.4) 198 (43.0) 146 (38.3) 165 (43.2)
Family history 0.13 0.001
Yes 82 (15.0) 54 (11.7) 104 (27.3) 67 (17.5)
No 465 (85.0) 407 (88.3) 277 (72.7) 315 (82.5)
Education 0.06 < 0.001
Less than high school 76 (13.9) 55 (11.9) 9 (2.4) 4 (1.1)
High school 175 (32.0) 122 (26.5) 80 (21.0) 44 (11.5)
College or above 296 (54.1) 284 (61.6) 292 (76.6) 334 (87.4)
Hormone replacement therapy 0.74 0.47
Yes 79 (14.5) 62 (14.2) 96 (25.3) 88 (23.0)
No 464 (85.5) 397 (85.8) 284 (74.7) 294 (77.0)
For continuous variables, P values were based on the t test; for categorical variables, P values were based on the chi-squared test. Owing to occasional missing
values, the counts of some variables did not add up to the total. SD, standard deviation.
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 A. Vitamin D severe deficiency (25OHD <10 ng/ml) 
B. Vitamin D receptor (VDR) expression in HapMap lymphoblastoid cell lines 
Figure 1 Serum 25OHD and vitamin D receptor expression in populations of African and European ancestry. (a) The bars indicate the
proportion of frank vitamin D deficiency - 25-hydroxyvitamin D (25OHD) of less than 10 ng/mL - and the 95% confidence interval. (b) The bars
indicate the average of the log2-transformed gene expression levels of vitamin D receptor (VDR) in the HapMap lymphoblastoid cell lines from
the CEU (Utah residents with ancestry from Northern and Western Europe) population and the YRI (Yoruba in Ibadan) population. The data were
obtained from Zhang and colleagues [32].
Yao et al. Breast Cancer Research 2012, 14:R58
http://breast-cancer-research.com/content/14/2/R58
Page 6 of 13
risk of ER- breast cancer, several SNPs in CYP24A1 were
highly significantly associated with risk of ER- breast
cancer. Importantly, results differed markedly between
AA and EA women (P for interaction was not more
than 0.10) (Table 3). For example, CYP24A1 rs27622941
was associated with a more than twofold increased risk
of ER- breast cancer among AA women (OR = 2.62,
95% CI = 1.38 to 4.98) and there were no associations
in EAs (OR = 0.78, 95% CI = 0.34 to 1.78). Conversely,
CYP24A1 rs2209314 was associated with an almost
threefold decreased risk of ER- breast cancer in EA
women (OR = 0.38, 95% CI = 0.20 to 0.73) and there
were no associations in AA women (OR = 1.34, 95% CI =
0.74 to 2.40).
To determine whether these SNPs contributed to the
observed higher risk of ER- breast cancer in AA women in
comparison with EA women, a base model containing
self-reported race and other covariates was developed
(Table 4). The base model showed an increased ER- cancer
risk associated with AA race (OR = 1.53, 95% CI = 1.06 to
2.22). The eight SNPs that showed significant interactions
with race were tested in the base model. After backward
selection, the two CYP24A1 SNPs shown above,
rs2209314 and rs2762941, remained significant in the final
model, reducing the risk associated with AA race by 22%
and rendering it non-significant (OR = 1.20, 95% CI =
0.80 to 1.79).
Lastly, there were significant interactions for two SNPs
in VDR with menopausal status (Table S5 of Additional
file 1). The increased risk associated with rs886441 in AA
women was restricted to pre-menopausal women (OR =
2.27, 95% CI = 1.32 to 3.90), and the increased risk asso-
ciated with rs7975232 (Apa1) in EA women was restricted
to post-menopausal women (OR = 2.24, 95% CI = 1.19 to
4.21).
Discussion
In this study, we found that relationships between breast
cancer risk and variants in genes associated with vitamin
D activity and metabolism, VDR and CYP24A1, differed
depending upon self-reported race and that associations
were most notable for risk of ER- breast cancer in both
AA and EA women. Importantly, we found that
rs2209314 and rs2762941 in CYP24A1 contributed sig-
nificantly to the higher risk of ER- breast cancer in AA
than EA women. Among controls in the WCHS, serum
levels of 25OHD were notably lower in AA women than
EA women, the lowest levels were among women with
the greatest African ancestry estimated by AIMs, and
VDR expression levels, as estimated from published data
Figure 2 Logarithm-transformed P values derived from univariate single-nucleotide polymorphism analysis of vitamin D receptor
(VDR). P values were plotted with accompanying linkage disequilibrium (LD) map for African-American (a) and European-American (b)
separately.
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Figure 3 Logarithm-transformed P values derived from univariate single-nucleotide polymorphism analysis of CYP24A1. P values were
plotted with accompanying linkage disequilibrium (LD) map for African-American (a) and European-American (b) separately.
Table 2 Single-nucleotide polymorphisms in VDR and CYP24A1 and differential associations with breast cancer risk
between African-American and European-American women in the Women’s Circle of Health Study
African-American European-American
Gene SNP Genotype Cases/Controls Adjusted OR
(95% CI)
Ptrend Cases/Controls Adjusted OR
(95% CI)
Ptrend Pinteraction
VDR rs11608702 AA 330/261 1.00 0.37 166/190 1.00 0.02 0.01
AT 175/175 0.80 (0.61-1.04) 160/159 1.15 (0.84-1.58)
TT 37/25 1.13 (0.65-1.95) 55/31 1.88 (1.14-3.09)
VDR rs12721364 GG 520/420 1.00 0.01 303/298 1.00 0.90 0.02
GA/AA 24/40 0.53 (0.31-0.90) 78/82 0.98 (0.68-1.41)
VDR rs2239186 AA 497/393 1.00 0.001a 265/256 1.00 0.46 0.01
AG/GG 47/68 0.53 (0.35-0.79) 115/125 0.85 (0.62-1.17)
VDR rs11568820 (Cdx2) GG 18/26 1.00 0.04 234/232 1.00 0.68 0.04
GA 143/140 1.55 (0.79-3.03) 129/132 0.99 (0.72-1.36)
AA 384/295 1.94 (1.01-3.74) 18/18 0.83 (0.39-1.75)
CYP24A1 rs912505 AA 173/139 1.00 0.71 236/216 1.00 0.02 0.05
AG 268/244 0.89 (0.66-1.19) 132/139 0.80 (0.59-1.10)
GG 104/77 1.14 (0.78-1.66) 13/27 0.36 (0.17-0.76)
CYP24A1 rs3787555 CC 379/331 1.00 0.14 206/183 1.00 0.03 0.02
CA 154/123 1.17 (0.88-1.56) 149/155 0.81 (0.59-1.10)
AA 14/7 1.88 (0.73-4.83) 25/41 0.50 (0.28-0.89)
Odds ratio (OR) and 95% confidence interval (CI) are adjusted for covariates, including age, proportion of European ancestry, body mass index, family history of
breast cancer, and education. Ptrend was for genetic dose response by coding genotypes as 0, 1, and 2 on the basis of the number of variant alleles. Pinteraction
was for the differences in ORs between African-American and European-American women, and a Pinteraction of less than 0.10 was deemed significant.
aSingle-
nucleotide polymorphism (SNP) rs2239186 in VDR remained significant after correction for multiple comparison by permutation.
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on cultured lymphoblastoid cells [32], were also lower in
AA women. In a previous study among EA women, we
found that low 25OHD levels were associated with
increased risk of ER- breast cancer, both in comparison
with controls and with women with ER+ breast cancer
[22]. Given all of these data, it is possible that low
25OHD levels in AA women, coupled with unique ‘at-
risk’ genetic variants, contribute, in part, to the higher
prevalence of ER- breast cancer among AA women. If
these potential associations were to be consistently
observed in future studies, our results would support a
public health effort for vitamin D supplementation to
reduce risk of aggressive breast cancer among AA
women.
Table 3 Single-nucleotide polymorphisms in VDR and CYP24A1 and differential association with estrogen receptor-
specific breast cancer risk among African-American and European-American women
African-American European-American
Gene SNP Genotype Cases/Controls OR (95% CI) Ptrend Cases/Controls OR (95% CI) Ptrend Pinteraction
VDR rs10783218 GG 178/304 1.00 0.82 194/352 1.00 0.04 0.04
GA/AA 85/150 0.96 (0.69-1.34) 20/17 2.05 (1.02-4.12)
VDR rs3819545 AA 71/242 1.00 0.04 22/162 1.00 0.38 0.04
AG 45/168 0.91 (0.59-1.40) 26/156 1.22 (0.66-2.26)
GG 3/43 0.23 (0.07-0.77) 11/52 1.40 (0.62-3.15)
CYP24A1 rs927650 GG 66/258 1.00 0.62 10/116 1.00 0.003 0.10
GA 47/170 1.09 (0.71-1.68) 29/186 1.76 (0.81-3.78)
AA 8/27 1.18 (0.50-2.79) 20/68 3.46 (1.50-7.96)
CYP24A1 rs1570669 GG 15/81 1.00 0.69 32/158 1.00 0.03 0.05
GA 69/219 1.77 (0.94-3.31) 24/162 0.71 (0.40-1.27)
AA 37/154 1.36 (0.69-2.67) 3/50 0.28 (0.08-0.97)
CYP24A1 rs2209314 AA 102/393 1.00 0.33 46/208 1.00 0.004 0.003
AG/GG 19/61 1.34 (0.74-2.40) 13/162 0.38 (0.20-0.73)
CYP24A1 rs3787555 CC 79/326 1.00 0.02 25/175 1.00 0.91 0.09
CA 37/122 1.42 (0.90-2.24) 29/155 1.25 (0.69-2.24)
AA 5/7 3.79 (1.11-12.91) 5/38 0.83 (0.30-2.35)
CYP24A1 rs2762941 AA 16/120 1.00 0.004 24/132 1.00 0.54 0.05
AG 61/212 1.97 (1.07-3.61) 26/168 0.89 (0.49-1.65)
GG 44/122 2.62 (1.38-4.98) 9/68 0.78 (0.34-1.78)
CYP24A1 rs4809959 GG 32/133 1.00 0.99 14/131 1.00 0.01 0.07
GA 64/223 1.13 (0.70-1.83) 26/172 1.43 (0.71-2.88)
AA 25/98 0.98 (0.54-1.78) 19/66 2.71 (1.25-5.86)
CYP24A1 rs2585428 GG 27/109 1.00 0.65 26/90 1.00 0.006 0.02
GA 66/246 1.12 (0.67-1.87) 22/175 0.46 (0.24-0.87)
AA 28/100 1.15 (0.63-2.10) 11/105 0.36 (0.17-0.79)
Odds ratio (OR) and 95% confidence interval (CI) are adjusted for covariates, including age, proportion of European ancestry, body mass index, family history of
breast cancer, and education. Ptrend was for genetic dose response by coding genotypes as 0, 1, and 2 on the basis of the number of variant alleles. Pinteraction
was for the differences in ORs between African-American and European-American women, and a Pinteraction of less than 0.10 was deemed significant. SNP, single-
nucleotide polymorphism.
Table 4 Changes in risk of estrogen receptor-negative breast cancer by race with inclusion of single-nucleotide
polymorphisms in CYP24A1
Model Variable Adjusted OR (95% CI) P value
Base model Race (AA versus EA) 1.53 (1.06-2.22) 0.02
Base model + SNPs Race (AA versus EA) 1.20 (0.80-1.79) 0.38
rs2209314 (AG/GG versus AA) 0.57 (0.36-0.89) 0.01
rs2762941 (AG versus AA) 1.47 (0.96-2.25) 0.04
rs2762941 (GG versus AA) 1.88 (1.15-3.06)
Covariates included in the base model were age at diagnosis, body mass index, family history of breast cancer, education, and race. Odds ratio (OR) and 95%
confidence interval (CI) for race after adjustment for other covariates are shown. Based on this model, seven single-nucleotide polymorphisms (SNPs) in CYP24A1
(rs927650, rs1570669, rs2209314, rs3787555, rs2762941, rs4809959, and rs2585428) and one SNP in VDR (rs3819545) that were associated with estrogen receptor-
negative (ER-) breast cancer risk in either African-American (AA) or European-American (EA) women were entered and backward-selected. Two SNPs, rs2209314
and rs2762941, remained in the final model with a P value of less than 0.05. ORs and 95% CIs for race and the two SNPs are shown.
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The finding of an inverse association between African
ancestry estimated by AIMs and blood 25OHD levels is
consistent with a recent community cohort study of AA
men and women [33]. Our findings of extensive racial
differences in allele frequencies and LD patterns for
SNPs in VDR and CYP24A1 are also consistent with
those from an earlier study [12]. Previous studies on VDR
polymorphisms and breast cancer risk have focused on
only a few SNPs. However, we did not find any relation-
ship with Fok1, Bsm1, or Taq1 or a three-SNP haplotype
consisting of Bsm1, Apa1, and Taq1 in either AA or EA
women. The variant homozygote of Apa1 was associated
with increased risk of breast cancer in EA women, but
the effect was limited to post-menopausal women.
Increased risk of breast cancer was also reported in a pre-
vious study for Apa1 [34]; however, results in the litera-
ture are conflicting [35,36]. The G allele of Cdx2 was
associated with lower risk of breast cancer in AA women
in our study and this finding was in contrast to the
speculated functional alteration that the variant G allele
resulted in lower binding of the Cdx2 protein and thus
lower transcriptional activity of VDR [37,38]. Similar to a
study among women in Germany [39], our study found
no association of Cdx2 with breast cancer risk in EA
women.
To date, three studies have examined selected SNPs in
VDR with breast cancer risk in both AA and EA women.
Two of them did not find associations for Fok1, Bsm1,
Bgl1 (rs739837), or the 3’ untranslated region poly(A)
microsatellite in either AA or EA women [40,41], and a
third study found increased risk by Bsm1 variant in EA
but not AA women [42]. However, none of the above stu-
dies examined the associations by ER status or used the
systematic approach we employed to capture variation
across the genes.
We found that four SNPs in VDR and two SNPs in
CYP24A1 had differential associations with breast cancer
by race (P for interaction was not more than 0.10). The
fact that the associations were not consistent in AA and
EA populations corroborates the differences in blood
levels of vitamin D and frequency and LD pattern of
vitamin D-related genetic variants, implying that the race-
specific associations might be the result of gene-environ-
ment interactions. In further analyses stratified by ER
status, one SNP in VDR and seven SNPs in CYP24A1
were specifically associated with ER- but not ER+ cancer
risk, and the associations differed between AA and EA
women. Controlling for the two SNPs in CYP24A1 in a
multivariate model substantially reduced the increased ER-
breast cancer risk associated with AA race and made the
association no longer significant. This provides the first
evidence supporting the contribution of vitamin D-related
genetic variants to higher risk of more aggressive breast
cancer in AA women.
We found significant associations between breast cancer
risk and a number of tag SNPs in VDR without previously
known functionality. However, in our analyses, SNP
rs2239186 was associated with increased serum levels of
25OHD in AA women without breast cancer. This SNP
and a haplotype containing it were also significantly asso-
ciated with reduced breast cancer risk in AA women, irre-
spectively of ER status. This SNP resides in an intronic
region and thus is unlikely to be the causal variant. How-
ever, it may be a marker for a causal SNP outside of the
VDR gene. This SNP has not been implicated in other
breast cancer studies but has been shown to be associated
with reduced risk of colorectal cancer in individuals with
low vitamin D intake [43] and was also implicated in type
I diabetes [44]. This SNP may warrant future replication
and fine-mapping studies.
The two SNPs, rs2209314 and rs2762941, in CYP24A1
shown to be associated with racial differences in ER- breast
cancer risk are intronic. Although these SNPs have not
been implicated previously in breast cancer, elevated
expression of CYP24A1 was found in breast cancer tissues
[45], indicating a potential role in breast cancer etiology.
We did not observe associations of these two SNPs in
CYP24A1 with serum 25OHD levels in either AA or EA
populations, indicating that these two SNPs themselves or
linked causal variants may affect ER- breast cancer not
through altering circulating 25OHD levels but availability
of vitamin D in local mammary tissues.
One limitation of our study is the lack of validation for
the significant findings. The number of patients with
breast cancer and controls was relatively limited, especially
after stratification by race and ER status. None of the asso-
ciations with SNPs, except for rs2239186, remained signifi-
cant after correction for multiple comparisons. We thus
could not exclude the possibility of false-positive findings
in our data. However, the fact that rs2239186 was asso-
ciated with higher serum 25OHD levels in AA women as
well as reduced breast cancer risk in this population is bio-
logically coherent and reduces the likelihood of spurious
findings for this VDR SNP. Another limitation is that only
three genes in vitamin D-related pathways were included
in this study. Although VDR, CYP27B1, and CYP24A1 are
the three key genes in this pathway, genes encoding for
some other vitamin D metabolizing enzymes, particularly
GC encoding for vitamin D binding protein (which has
been related to circulating vitamin D levels), may also be
related to breast cancer risk and warrant further studies.
AA women are more likely to develop breast cancer at a
younger age than EAs; we enrolled all eligible AA women
but randomly selected eligible EA women, frequency-
matching by 5-year age categories. We also initially limited
eligibility to women 65 years or younger because of low
participation of older women without breast cancer to
case-control studies. Thus, the overall study population is
Yao et al. Breast Cancer Research 2012, 14:R58
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younger than that of some other studies. Although we
found no evidence of modification effects by menopausal
status for any but two SNPs (Table S5 of Additional file
1), the high proportion of pre-menopausal women in this
study needs to be considered in relation to generalizability.
Conclusions
We found notable differences in blood levels of 25OHD
and genetic variants in VDR and CYP24A1 between AA
and EA women. Specifically, we found race-specific
associations with breast cancer risk and these associa-
tions may be due to distinct genetic background and dif-
ferences in 25OHD levels between the two populations.
Our study provides evidence that variants in vitamin D-
related genes may contribute to higher risk of ER- breast
cancer in AA than EA women. Future studies are war-
ranted to validate our findings and to investigate
whether pre-diagnostic blood levels of 25OHD may also
be related to racial differences in risk of ER- breast
cancer.
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